Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02024867 · ClinicalTrials.gov registry record · NA

Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

A NA study of Abscess and Skin Disease, Bacterial, sponsored by Lucy Holmes, MD.

Completed
Registry status
NA
Development phase
249
Enrollment target
1
Study location

NCT02024867 is a NA study of Abscess and Skin Disease, Bacterial that has completed, run by Lucy Holmes, MD. The registered enrollment target is 249 participants, below the 371-participant average among 13 other Abscess trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02024867, a NA study of Abscess and Skin Disease, Bacterial, has completed, sponsored by Lucy Holmes, MD.

COMPLETED
Registry status
NA
Development phase
249 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to determine if there is a difference in treatment failures and recurrent skin infections when patients are given 3 or 10 days of antibiotics for uncomplicated skin abscesses after they have been surgically drained.

Interventions

  • DRUG Trimethoprim-Sulfamethoxazole

Study Locations (1)

New York

  • Women & Children's Hospital of Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 249 participants
Start Date 2010-02
Est. Completion 2012-07
Phase NA

Sponsor

Lucy Holmes, MD

1 total trials

What the Registry Record Tells You About NCT02024867

The ClinicalTrials.gov registry entry for NCT02024867 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 371-participant average among 13 other Abscess trials with a reported enrollment target (33% lower). The listed sponsor is Lucy Holmes, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Abscess appearing as the primary indexed condition, and to 1 intervention - of which Trimethoprim-Sulfamethoxazole is the first listed.

NCT02024867 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02024867 about?

NCT02024867 is a clinical study titled "Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage". The objective of this study is to determine if there is a difference in treatment failures and recurrent skin infections when patients are given 3 or 10 days of antibiotics for uncomplicated skin abscesses after they have been surgically drained.

What is the current status of trial NCT02024867?

This trial is currently completed. It is a NA study. The enrollment target is 249 participants. The study started on 2010-02. Estimated completion is 2012-07.

What conditions does trial NCT02024867 study?

This clinical trial studies the following conditions: Abscess, Skin Disease, Bacterial.

What interventions are being tested in trial NCT02024867?

The interventions under investigation include: Trimethoprim-Sulfamethoxazole (DRUG).

Who is sponsoring clinical trial NCT02024867?

This trial is sponsored by Lucy Holmes, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02024867 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Abscess

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.